Comparative Analysis of Bioactivity of the Russian-Made Antitumor Substances of the Nitrosourea Group


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

We performed an in vivo comparative study of activity of three substances of the nitrosourea group produced in Russia. All substances demonstrated high antitumor activity against various solid and leukemic tumors. Aranosa significantly enhanced life duration in mice with leukemia (by 65-194%) and inhibited the growth of solid tumors (by 49-99.6%). Lisomustine and ormustine showed higher activity than aranose. Single administration of lisomustine increased life span of mice (by 22-114%) and resulted in cure of all animals in four models: lymphoblastic leukemia L-1210, lymphocytic leukemia P-388, Lewis lung carcinoma, and cervical cancer RShM-5. After ormustine treatment, full recovery was observed only in groups with lymphocytic leukemia P-388 and cervical cancer RShM-5. These findings attest to higher activity of lisomustine in the studied models.

Об авторах

N. Bunyatyan

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Автор, ответственный за переписку.
Email: ndbun@mail.ru
Россия, Moscow; Moscow

N. Oborotova

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow; Moscow

L. Nikolaeva

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow; Moscow

N. Saprykina

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow

L. Borisova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow

M. Kiseleva

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow

A. Prokof’ev

I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Email: ndbun@mail.ru
Россия, Moscow; Moscow


© Springer Science+Business Media, LLC, part of Springer Nature, 2019

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах